Magazine Article | April 1, 2022

Companies To Watch: Global Blood Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Intertwining science, business, and social missions to make progress against sickle cell disease

SNAPSHOT

Global Blood Therapeutics (GBT) is developing new therapeutics for blood disorders, chiefly sickle cell disease (SCD), while also rallying the SCD community to seek and receive treatment. In November 2019, with Oxbryta (voxelotor), the company won the first-ever FDA approval of a significant new drug for treating SCD. Oxbryta earned accelerated approval based on increased hemoglobin, which the disease severely depresses. Oxbryta also appears to reduce pain and lower the incidence of vaso-occlusive crises (VOCs). Another product, inclacumab, is in Phase 3 trials for preventing and reducing hospital admissions for VOCs. A third candidate, coded GBT021601, is in early clinical development to deter sickling and destruction of red blood cells (RCBs). Potential therapeutics are in discovery, offering new approaches to SCD. GBT is also exploring new treatments for other blood disorders, such as beta thalassemia.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: